Studies have shown that during the cellular senescence process caused by tumor treatment, the sensitivity of senescent tumor cells to BCL‐xl inhibitors increases significantly, and notably, the inhibition of cellular senescence in cells with increased sensitivity to BCL‐xl inhibitors is limited to those whose effects are mediated via ADP ribose polymerase 1 (e.g., senescent cells caused by DNA damage induced by ARP). The gene discussed is BCL2L1; the disease is neoplasm.